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We present retrospectively our experience in the use of high-dose chemotherapy and haematopoietic stem cell support (HSCS) for
refractory gestational trophoblastic neoplasia (GTN) in the largest series so far reported. In all, 11 patients have been treated at three
Trophoblast Centres between 1993 and 2004. The conditioning regimens comprised either Carbop-EC-T (carboplatin, etoposide,
cyclophosphamide, paclitaxel and prednisolone) or CEM (carboplatin, etoposide and melphalan) or ICE (ifosfamide, carboplatin,
etoposide). Two patients had complete human chorionic gonadotrophin responses, one for 4 and the other for 12 months. Three
patients had partial tumour marker responses for 1–2 months. High-dose chemotherapy and HSCS for GTN is still unproven.
Further studies are needed, perhaps in high-risk patients who fail their first salvage treatment.
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Occasional patients with gestational trophoblastic neoplasia (GTN)
will have an incomplete response to conventional chemotherapy or
will relapse from remission. There have been several case reports
of high-dose chemotherapy (HDC) and haematopoietic stem cell
support (HSCS) in patients with refractory GTN (Collins et al,
1991; Giacalone et al, 1995; Lotz et al, 1995; Nagatoshi et al, 1996;
Chou et al, 1997; van Besien et al, 1997; Aoki et al, 1999; Knox
et al, 2002). The results have been mixed and no clear prognostic
scoring system has been developed to identify which patients may
benefit from HDC.
MATERIALS AND METHODS
In all, 11 patients with refractory or relapsing GTN were treated
with HDC and HSCS at three supraregional trophoblast centres
(Charing Cross Hospital, London, UK, Weston Park Hospital,
Sheffield, UK and Waikato Hospital, New Zealand) between 1993
and 2004. Three conditioning regimens have been used: the Carbo-
EC-T regimen (Charing Cross Hospital) included paclitaxel
75mgm
 2, etoposide 450mgm
 2, carboplatin with AUC 10 on
days  7,  5 and  3, cyclophosphamide 60mgkg
 1þmesna on
days  5 and  3 and prednisolone 30mg twice daily on days 0–14.
The CEM regimen (Weston Park Hospital) included carboplatin
(AUC 15), etoposide 100mgm
 2b.d. days  5t o 2 and
melephalan 140mgm
 2 day  1. The ICE regimen (Waikato
Hospital) included ifosfamide 2.5gmm
 2þmesna days  6t o
 3, carboplatin 500mgm
 2 days  6t o 4 and etoposide
600mgm
 2 days  6t o 3.
RESULTS
Six patients had choriocarcinoma (CC), one patient had placental
site trophoblastic tumour (PSTT) and one a mixed dimorphic (CC
and PSTT) tumour. Gestational trophoblastic neoplasia followed
abortions in five patients, term pregnancy in three and complete
hydatidiform mole in three. Four patients were initially judged as
low and six high risk. The patient with PSTT was widely metastatic
from presentation. The median number of prior chemotherapy
regimens was 3 (ranges 1–5). Three patients had falling hCG prior
to HDC, and eight had plateaued and five had rising hCG.
One patient had a complete hCG response to the CEM regimen
lasting 4 months. Another patient had a complete hCG response to
two cycles of ICE and remains disease free at 12 months. Both of
the latter two patients scored 1 on the Beyer scoring system (Beyer
et al, 1996), and had falling hCG levels on salvage chemotherapy
prior to HDC. Two patients with plateaued hCG levels on prior
salvage chemotherapy had a partial hCG response for 4 months
(one with Carbop-EC-T and one with CEM). The other patients
had progressive disease.
DISCUSSION
In patients with refractory GTN, HDC and HSCS has been reported
in a limited number of studies. Lotz et al (1995) treated five
patients refractory to standard therapy, with HDC consisting of
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sifosfamide, carboplatin, and etoposide and HSCS. Two patients
had normalisation of their hCG levels for 68 days and 2 months,
respectively. Collins et al (1991), Giacalone et al (1995) and van
Besien et al (1997) each reported on one patient with refractory
GTN who achieved complete response (CR) with HDC. Knox et al
(2002) reported on a patient with recurrent post-term CC who was
treated with an HDC regimen, consisting of cyclophosphamide,
etoposide, and carboplatin, and HSCS and had no evidence of
disease 23 months post-transplant. On the other hand, Aoki et al
(1999) reported failure of HDC and HSCS in a patient with
refractory PSTT.
Chou et al (1997) reported on a 39-year-old woman with
metastatic and resistant nongestational ovarian CC who was
treated with HDC (carboplatin, etoposide and ifosfamide) and
HSCS with surgical resection of two metastatic lung lesions. The
patient obtained CR and remained disease free 17 months later.
Similarly, Nagatoshi et al (1996) reported on a successful outcome
with similar treatment for an adolescent male patient with
retroperitoneal pure CC and multiple brain metastases.
In our series, which although retrospective is the largest so far
reported, 11 patients were treated for refractory GTN with HDC
and HSCS. Most of these cases had suffered multiple relapses and/
or resistance to treatment despite the use of the standard first-line
chemotherapies as well as a variety of intensive salvage treatments.
Most patients (70%) had initially been assessed as high risk. Either
Carbop-EC-T (carboplatin, etoposide, cyclophosphamide, pacli-
taxel, prednisolone) or the CEM regimen (carboplatin, etoposide
and melphalan) or the ICE regimen (ifosfamide, carboplatin,
etoposide) was used.
Two patients had complete hCG responses; one had originally
had hydatidiform mole, stratified as low risk and received five
different chemotherapy regimens for disease recurrence with lung
and brain metastases. She also had hysterectomy and pulmonary
and cerebral metastatectomy followed by an ifosfamide/taxol
regimen with complete hCG response. This marker remission
was consolidated with HDC and HSCS. She remained disease free
with hCG CR for 4 months following transplant. The other patient
had originally had hydatidiform mole, stratified as low risk and
received four different chemotherapy regimens, as well as having
pulmonary and cerebral metastatectomy for recurrent metastatic
disease. She received a tandem transplant with the ICE regimen
with complete hCG response and was still alive and disease free 12
months post-transplant. The two patients who had complete hCG
response each scored 1 on the Beyer system. Three other patients
in our study showed 1–2 months partial hCG response to HDC
and HSCS; one of them had initially a persistent hydatidiform
mole, judged as low risk; the other two patients had CC and were
categorised as high risk at initial diagnosis. All three patients each
received three different chemotherapy regimens prior to HDC with
Carbop-EC-T. All patients who showed a response to HDC and
HSCS had had an hCG response to the salvage regimen prior to
HDC, which might reflect the chemosensitivity of their disease and
could be a clue for proceeding to HDC.
In conclusion, HDC and HSC support for GTN is still
investigational and reported in a small number of cases. The cases
reported here suggest that, while HDC may be an option, further
studies are needed, perhaps in patients with high-risk GTN who
fail their first salvage treatment for recurrent disease.
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